Models for open innovation in the pharmaceutical industry

被引：82

作者：

Schuhmacher, Alexander ^{[1
]}

Germann, Paul-Georg ^{[2
]}

Trill, Henning ^{[3
]}

Gassmann, Oliver ^{[4
]}

机构：

[1] Reutlingen Univ, Sch Appl Chem, D-72762 Reutlingen, Germany

[2] Takeda Pharmaceut Int Inc, D-78467 Constance, Germany

[3] Bayer Business Serv GmbH, D-51368 Leverkusen, Germany

[4] Univ St Gallen, Inst Technol Management, CH-9000 St Gallen, Switzerland

来源：

DRUG DISCOVERY TODAY | 2013年 / 18卷 / 23-24期

关键词：

D O I：

10.1016/j.drudis.2013.07.013

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The nature of the pharmaceutical industry is such that the main driver for its growth is innovation. In view of the vast challenges that the industry has been facing for several years and, in particular, how to manage stagnating research and development (R&D) productivity, pharmaceutical companies have opened their R&D organizations to external innovation. Here, we identify and characterize four new types of open innovator, which we call 'knowledge creator', 'knowledge integrator', 'knowledge translator' and 'knowledge leverager', and which describe current open R&D models.

引用

页码：1133 / 1137

页数：5

共 18 条

[1]

[Anonymous], 2010, SHIRE ANN CO REPORT

[2]

Chesbrough H., 2003, OPEN INNOVATION

[3] Macro trends in pharmaceutical innovation [J].

Cohen, FJ .

NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (01) :78-84

[4]

Ernst&Young, 2010, BORD GLOB BIOT REP 2

[5]

European Commission Joint Research Centre Directorate General Research, 2012, 2012 EU IND R D INV

[6] 2008 FDA drug approvals [J].

Hughes, Bethan .

NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (02) :93-96

[7] Is open innovation the way forward for big pharma? [J].

Hunter, Jackie ;

Stephens, Susie .

NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (02) :87-88

[8]

*IMAP, 2011, PHARM BIOT IND GLOB

[9]

International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), 2011, PHARM IND GLOB HLTH

[10] Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000-2009 [J].

Kaitin, K. I. ;

DiMasi, J. A. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (02) :183-188

← 1 2 →